Phase 1b Partially-blind,Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of NDV-3, A Recombinant Alum Adjuvanted Vaccine for S. Aureus and Candida Infections, Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults

Trial Profile

Phase 1b Partially-blind,Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of NDV-3, A Recombinant Alum Adjuvanted Vaccine for S. Aureus and Candida Infections, Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 28 May 2013

At a glance

  • Drugs NDV 3 (Primary) ; Aluminium hydroxide
  • Indications Candidiasis; Staphylococcal infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 May 2012 Status changed from recruiting to completed, according to a NovaDigm Therapeutics media release.
    • 10 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top